{"id":28998,"date":"2025-03-12T22:30:00","date_gmt":"2025-03-12T17:00:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=28998"},"modified":"2025-03-12T21:15:59","modified_gmt":"2025-03-12T15:45:59","slug":"wegovy-for-obesity-and-weight-loss","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/wegovy-for-obesity-and-weight-loss","title":{"rendered":"WEGOVY: A Leader in the Obesity and Weight Loss Treatment"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69dc575320ae1\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69dc575320ae1\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/wegovy-for-obesity-and-weight-loss\/#WEGOVYs_Label_Expansion_in_Cardiovascular\" >WEGOVY\u2019s Label Expansion in Cardiovascular<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/wegovy-for-obesity-and-weight-loss\/#Approval_in_China_Added_Another_Feature_in_Cap_to_WEGOVY\" >Approval in China Added Another Feature in Cap to WEGOVY<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/wegovy-for-obesity-and-weight-loss\/#WEGOVYs_Triumph_at_American_Diabetes_Association_2024\" >WEGOVY\u2019s Triumph at American Diabetes Association 2024<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/wegovy-for-obesity-and-weight-loss\/#What_Lies_Ahead_for_WEGOVY\" >What Lies Ahead for WEGOVY?<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>With the growing global health concern regarding obesity, <strong>Novo\u2019s WEGOVY (semaglutide)<\/strong> has emerged as a leading solution in the weight loss treatment market. WEGOVY is a <strong>GLP-1 receptor agonist<\/strong> used alongside a low-calorie diet and increased physical activity. This obesity medication is administered as a <strong>weekly subcutaneous injection<\/strong>, offering convenience and consistency in <a href=\"https:\/\/www.delveinsight.com\/blog\/obesity-treatment-landscape\">obesity management<\/a>.<\/p>\n\n\n\n<p>In June 2021, the FDA approved WEGOVY injections for long-term weight management in adults. This obesity drug\u2019s approval marked a significant milestone in the field of obesity treatment. WEGOVY has been a dominant force in the lucrative obesity market, which is poised to reach <strong>$12 billion<\/strong> by 2034 in the US, as per DelveInsight.<\/p>\n\n\n\n<p>As per the estimates, semaglutide captured <strong>~60%<\/strong> of the <strong>$2.8 billion<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-market\">weight loss treatment market<\/a> in 2023 thanks to its superior weight loss effectiveness. Novo Nordisk&#8217;s obesity care products saw a remarkable 147% sales surge, fueled by WEGOVY\u2019s rapid adoption and 70% commercial formulary access within six months of launch. To meet rising demand, the company increased lower-dose WEGOVY supply in January 2024. In <strong>February 2025, <\/strong>Novo Nordisk reported a <strong>30% Q4 2024<\/strong> sales growth, reaching <strong>$12 billion<\/strong>, contributing to a <strong>26% annual sales <\/strong>increase to nearly <strong>$41 billion. <\/strong>The company also posted<strong> $18 billion <\/strong>in operating profits for 2024, as per its latest press release.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-wegovy-s-label-expansion-in-cardiovascular\"><span class=\"ez-toc-section\" id=\"WEGOVYs_Label_Expansion_in_Cardiovascular\"><\/span><strong>WEGOVY\u2019s Label Expansion in Cardiovascular<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Novo Nordisk\u2019s rapidly expanding WEGOVY weight loss medication has received new cardiovascular approval from the FDA in March 2024, which could boost its already impressive reputation even further. It is now the first obesity medication to be approved by the FDA for lowering the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease who are obese or overweight.<\/p>\n\n\n\n<p>The FDA approved obesity drug WEGOVY based on <a href=\"https:\/\/www.delveinsight.com\/blog\/top-highlights-from-ada-conference-2024\"><strong>Novo\u2019s SELECT cardiovascular outcomes study<\/strong><\/a>, which evaluated Wegovy over five years in 17,604 patients who were obese or overweight, had existing cardiovascular disease, and had no history of diabetes.<\/p>\n\n\n\n<p>WEGOVY treatment reduced the risk of major adverse cardiovascular events by 20% compared to a placebo when combined with standard blood pressure and cholesterol management, as well as lifestyle changes like diet and exercise. The benefits of the obesity drug persisted for up to five years, regardless of initial body mass index or kidney function. WEGOVY also led to a 15% decrease in the risk of cardiovascular death and a 19% reduction in the risk of death from any cause.<\/p>\n\n\n\n<p>The recent approval could significantly intensify the <a href=\"https:\/\/www.delveinsight.com\/blog\/transforming-obesity-treatment\">competition between Novo\u2019s product and Eli Lilly\u2019s ZEPBOUND<\/a>. Novo\u2019s growth has been driven by the success of WEGOVY and other semaglutide-based drugs since WEGOVY\u2019s debut in 2021. Due to high demand, the company has struggled with supply shortages. After a prior pause in marketing, Novo reintroduced WEGOVY in January and has since more than doubled its supply of starter doses.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"337\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/12211346\/WEGOVY-Roadmap-1024x337.png\" alt=\"WEGOVY Roadmap\" class=\"wp-image-31261\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/12211346\/WEGOVY-Roadmap-1024x337.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/12211346\/WEGOVY-Roadmap-300x99.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/12211346\/WEGOVY-Roadmap-150x49.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/12211346\/WEGOVY-Roadmap-768x253.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/12211346\/WEGOVY-Roadmap-1536x506.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/12211346\/WEGOVY-Roadmap-2048x674.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-approval-in-china-added-another-feature-in-cap-to-wegovy\"><span class=\"ez-toc-section\" id=\"Approval_in_China_Added_Another_Feature_in_Cap_to_WEGOVY\"><\/span><strong>Approval in China Added Another Feature in Cap to WEGOVY<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Novo Nordisk\u2019s diabetes medication <strong>OZEMPIC (semaglutide)<\/strong> has been available in China for three years and is quickly approaching blockbuster sales in the world\u2019s second most populous country. Building on this success, the Danish company is now set to intensify its efforts with its obesity treatment, WEGOVY.<\/p>\n\n\n\n<p>On June 25, 2024, China\u2019s National Medical Products Administration (NMPA) granted WEGOVY approval for marketing as a treatment for individuals with a body mass index (BMI) of 30 or higher, or between 27 and 30 for those with one weight-related risk factor. In China, it will be sold under the name <strong>NovoCare<\/strong>. The obesity medication is the same semaglutide compound used in OZEMPIC.<\/p>\n\n\n\n<p>This <a href=\"https:\/\/www.delveinsight.com\/report-store\/wegovy-semaglutide-drug-insight-and-market-forecast\">WEGOVY weight loss drug<\/a> approval is creating a new multimillion-dollar opportunity for the Danish pharmaceutical company. However, this approval arrived at the wrong time as the semaglutide patent will expire in two years and the competition from biosimilars in China is intensifying. Whereas, in Europe and the United States, Novo holds the exclusive rights to semaglutide until <strong>2031 and 2032<\/strong>, respectively.<\/p>\n\n\n\n<p>Novo has initiated a legal campaign to prolong its patent, yet over <strong>15 generic versions<\/strong> of semaglutide are currently being developed in China, with multiple ones already in advanced trial stages. To back WEGOVY\u2019s debut in China, Novo has been heavily investing in its local manufacturing infrastructure. In March, the pharmaceutical company revealed a <strong>\u00a54 billion (over $500 million)<\/strong> investment in its Tianjin facility. Scheduled for completion by 2027, the expansion aims to boost production capacity to satisfy the growing demand for its products in China.<\/p>\n\n\n\n<p>Meanwhile, Novo is bolstering its manufacturing presence in the US to help safeguard its market share in the event of losing semaglutide patent exclusivity. Last year, Novo significantly increased its OZEMPIC sales in China to <strong>4.82 billion kroner ($693 million)<\/strong>. However, the company now encounters competition in this area, as the NMPA recently approved Eli Lilly\u2019s dual-action GLP-1\/GIP diabetes medication, <a href=\"https:\/\/www.delveinsight.com\/blog\/eli-lillys-obesity-treatment-drug-candidates\"><strong>MOUNJARO (tirzepatide)<\/strong><\/a>, which will be marketed in China under the name <strong>MuFengDa<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-wegovy-s-triumph-at-american-diabetes-association-2024\"><span class=\"ez-toc-section\" id=\"WEGOVYs_Triumph_at_American_Diabetes_Association_2024\"><\/span><strong>WEGOVY\u2019s Triumph at American Diabetes Association 2024<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Research presented at the <a href=\"https:\/\/www.delveinsight.com\/blog\/tag\/american-diabetes-association-2024\">American Diabetes Association\u2019s 2024 Scientific Sessions<\/a> and published in the Journal of the American College of Cardiology found that Novo Nordisk\u2019s highly successful obesity medication, WEGOVY, led to more significant weight loss in women compared to men with a prevalent form of heart failure.<\/p>\n\n\n\n<p>The results are from <strong>Novo\u2019s STEP-HFpEF program<\/strong>, which included 1,145 patients with obesity-related heart failure with preserved ejection fraction in two trials. These studies mainly aimed to evaluate the impact of a 2.4-mg dose of semaglutide on health status, measured by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), and on weight loss.<\/p>\n\n\n\n<p>Approximately half of the participants were women, who, at the start of the study, had higher body mass index and C-reactive protein levels, as well as a greater left ventricular ejection fraction. Additionally, women experienced more severe heart failure symptoms compared to men at baseline.<\/p>\n\n\n\n<p>After 52 weeks of treatment, semaglutide caused considerable weight loss in both men and women, with men losing an average of 10.2% of their body weight and women losing 12.6%. Even when compared to placebo, the semaglutide weight loss effect was notably more significant in women, who experienced an adjusted mean reduction of 9.6% in body weight, versus 7.2% in men. This difference was statistically significant, with a p-value of 0.006 for the interaction.<\/p>\n\n\n\n<p>Regarding cardiovascular outcomes, semaglutide proved equally effective for both genders, improving the KCCQ-CSS score by 7.6 points in women and 7.5 points in men. Additionally, semaglutide led to significant improvements in the six-minute walk distance, with no differences observed between the sexes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-lies-ahead-for-wegovy\"><span class=\"ez-toc-section\" id=\"What_Lies_Ahead_for_WEGOVY\"><\/span><strong>What Lies Ahead for WEGOVY?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Semaglutide is a GLP-1 receptor agonist that stimulates insulin release from the pancreas in response to blood sugar levels. It is marketed as OZEMPIC for <a href=\"https:\/\/www.delveinsight.com\/report-store\/type-2-diabetes-market\">type 2 diabetes treatment<\/a> and as WEGOVY for chronic weight management. Novo Nordisk has recently expanded WEGOVY\u2019s approval to include reducing the risk of cardiovascular death, heart attack, and stroke in adults with obesity and cardiovascular disease.<\/p>\n\n\n\n<p>Additionally, the Danish pharmaceutical company is exploring semaglutide as a potential <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-kidney-disease-chronic-renal-failure-market\">treatment for kidney disease<\/a>. Results from the <strong>Phase III FLOW trial <\/strong>showed a 20% decrease in overall mortality among type 2 diabetes patients with chronic kidney disease.<\/p>\n\n\n\n<p>Currently, Novo\u2019s WEGOVY is facing stiff competition in the obesity treatment space from <strong>Eli Lilly\u2019s ZEPBOUND<\/strong>. ZEPBOUND, which was initially developed for type 2 diabetes, has recently received approval for obesity. According to DelveInsight\u2019s analysis, ZEPBOUND is expected to experience rapid growth and potentially dominate around <strong>35%<\/strong> of the obesity market by 2032. In February 2025, the company reported a <strong>30% increase<\/strong> in sales for <strong>Q4 2024<\/strong>, reaching <strong>$12 billion<\/strong> for <strong>WEGOVY<\/strong>. This helped total sales for <strong>2024 <\/strong>grow by <strong>26%,<\/strong> reaching nearly <strong>$41 billion,<\/strong> with operating profits of<strong> $18 billion,<\/strong> as announced in a press release.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"322\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/28141519\/ZEPBOUND-vs-WEGOVY-1024x322.png\" alt=\"ZEPBOUND vs WEGOVY\" class=\"wp-image-28521\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/28141519\/ZEPBOUND-vs-WEGOVY-1024x322.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/28141519\/ZEPBOUND-vs-WEGOVY-300x94.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/28141519\/ZEPBOUND-vs-WEGOVY-150x47.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/28141519\/ZEPBOUND-vs-WEGOVY-768x242.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/28141519\/ZEPBOUND-vs-WEGOVY-1536x484.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/28141519\/ZEPBOUND-vs-WEGOVY-1568x494.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/28141519\/ZEPBOUND-vs-WEGOVY.png 1921w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Furthermore, WEGOVY will also face tough competition from other obesity companies in the coming years as well.&nbsp; The current <a href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-obesity-treatment\">obesity development pipeline<\/a> includes <strong>more than <\/strong><strong>100 clinical-<\/strong><strong>stage assets<\/strong> in trials, primarily featuring GLP-1 receptor agonists, either used alone or in combination with GIP agonists.<\/p>\n\n\n\n<p>Obesity companies such as <strong>Novo Nordisk (Semaglutide oral), Eli Lilly and Company (Tirzepatide), Saniona (Tesomet), Raziel Therapeutics (RZL-012), Empros Pharma (EMP16), D&amp;D Pharmatech (DD01),<\/strong> and others are evaluating their anti-obesity medication in different stages of obesity clinical trials to grab some market share.<\/p>\n\n\n\n<p>Apart from these, several non-entero-pancreatic hormone treatments are being assessed, providing alternative options for weight loss because of their unique mechanisms. These new obesity therapies reflect the growing variety of approaches in obesity treatment, targeting the complex nature of the condition.<\/p>\n\n\n\n<p>In this setting, numerous pharmaceutical companies, such as <strong>Biolexis Therapeutics, Arrowhead Pharmaceuticals, and Viking Therapeutics<\/strong>, have shared their pre-clinical findings at the American Diabetes Association (ADA) 2024 session. Their presentations play a vital role in tackling the most complex issues of the new era in obesity management, highlighting a unified effort to enhance therapeutic approaches and boost patient outcomes.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-1024x194.png\" alt=\"Obesity-Market-Outlook-and-Assessment\" class=\"wp-image-28507\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-1568x297.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>With the growing global health concern regarding obesity, Novo\u2019s WEGOVY (semaglutide) has emerged as a leading solution in the weight loss treatment market. WEGOVY is a GLP-1 receptor agonist used alongside a low-calorie diet and increased physical activity. This obesity medication is administered as a weekly subcutaneous injection, offering convenience and consistency in obesity management. [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":28999,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[877,1173,19429,20479,19427,18881,19430,21050,18883,18880,22172],"industry":[17225],"therapeutic_areas":[18720],"class_list":["post-28998","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-novo-nordisk","tag-obesity","tag-obesity-companies","tag-obesity-drugs","tag-obesity-management","tag-obesity-market","tag-obesity-treatment","tag-wegovy","tag-weight-loss","tag-weight-loss-market","tag-zepbound","industry-pharmaceutical","therapeutic_areas-nutritional-disorders-and-weight-loss"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>WEGOVY: Leading the Charge in Weight Loss Treatment<\/title>\n<meta name=\"description\" content=\"As global health concerns about obesity rise, Novo\u2019s WEGOVY has become a prominent solution in the market for obesity treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/wegovy-for-obesity-and-weight-loss\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WEGOVY: Leading the Charge in Weight Loss Treatment\" \/>\n<meta property=\"og:description\" content=\"As global health concerns about obesity rise, Novo\u2019s WEGOVY has become a prominent solution in the market for obesity treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/wegovy-for-obesity-and-weight-loss\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-12T17:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/02114738\/wegovy-for-obesity-and-weight-loss.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"WEGOVY: Leading the Charge in Weight Loss Treatment","description":"As global health concerns about obesity rise, Novo\u2019s WEGOVY has become a prominent solution in the market for obesity treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/wegovy-for-obesity-and-weight-loss","og_locale":"en_US","og_type":"article","og_title":"WEGOVY: Leading the Charge in Weight Loss Treatment","og_description":"As global health concerns about obesity rise, Novo\u2019s WEGOVY has become a prominent solution in the market for obesity treatment.","og_url":"https:\/\/www.delveinsight.com\/blog\/wegovy-for-obesity-and-weight-loss","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-03-12T17:00:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/02114738\/wegovy-for-obesity-and-weight-loss.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/wegovy-for-obesity-and-weight-loss","url":"https:\/\/www.delveinsight.com\/blog\/wegovy-for-obesity-and-weight-loss","name":"WEGOVY: Leading the Charge in Weight Loss Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/wegovy-for-obesity-and-weight-loss#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/wegovy-for-obesity-and-weight-loss#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/02114738\/wegovy-for-obesity-and-weight-loss.png","datePublished":"2025-03-12T17:00:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"As global health concerns about obesity rise, Novo\u2019s WEGOVY has become a prominent solution in the market for obesity treatment.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/wegovy-for-obesity-and-weight-loss"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/wegovy-for-obesity-and-weight-loss#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/02114738\/wegovy-for-obesity-and-weight-loss.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/02114738\/wegovy-for-obesity-and-weight-loss.png","width":466,"height":284,"caption":"wegovy-for-obesity-and-weight-loss"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/02114738\/wegovy-for-obesity-and-weight-loss-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Novo Nordisk<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity companies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity management<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Obesity Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Wegovy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Weight Loss<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Weight Loss Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ZEPBOUND<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Novo Nordisk<\/span>","<span class=\"advgb-post-tax-term\">obesity<\/span>","<span class=\"advgb-post-tax-term\">obesity companies<\/span>","<span class=\"advgb-post-tax-term\">obesity drugs<\/span>","<span class=\"advgb-post-tax-term\">obesity management<\/span>","<span class=\"advgb-post-tax-term\">Obesity Market<\/span>","<span class=\"advgb-post-tax-term\">obesity treatment<\/span>","<span class=\"advgb-post-tax-term\">Wegovy<\/span>","<span class=\"advgb-post-tax-term\">Weight Loss<\/span>","<span class=\"advgb-post-tax-term\">Weight Loss Market<\/span>","<span class=\"advgb-post-tax-term\">ZEPBOUND<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Mar 12, 2025","modified":"Updated on Mar 12, 2025"},"absolute_dates_time":{"created":"Posted on Mar 12, 2025 10:30 pm","modified":"Updated on Mar 12, 2025 9:15 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28998","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=28998"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28998\/revisions"}],"predecessor-version":[{"id":31262,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28998\/revisions\/31262"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/28999"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=28998"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=28998"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=28998"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=28998"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=28998"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}